Clinical Trial Update: RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (RRISC) evaluating the Cypher sirolimus-eluting stent to reduce restenosis in saphenous vein grafts has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Saphenous Vein Graft Disease
• Stable Angina
• Unstable Angina

Drugs mentioned

• Cypher Sirolimus-Eluting Stent (sirolimus-eluting stent)

Snippet

Sponsor: Antwerp Cardiovascular Institute Middelheim | Conditions: Stable Angina, Unstable Angina | Phase 2 | Status: COMPLETED